RxSight stock falls 1.62 percent as target cuts mount

Published on 09/24/2026 at 01:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RxSight stock traded at USD 4.85 on September 23, 2026, below its USD 13.22 52-week high. Q2 revenue reached USD 33.74 million versus USD 32.55 million consensus.

RxSight stock, healthcare, medical devices, analyst target cuts, Nasdaq, Illustration mit AI erstellt.

RxSight stock (ISIN US78349D1072) stood at USD 4.85 in after-hours trading on Nasdaq on September 23, 2026, down 1.62 percent from the USD 4.93 prior close. The latest analyst revisions add pressure while the company works to restore growth in its light-adjustable lens business.

Target cuts reset valuation

Bank of America cut its RxSight price target from USD 6.50 to USD 5.50 and maintained an Underperform rating in a research note dated September 22, 2026, according to MarketBeat.

Jefferies also reduced its target from USD 6.50 to USD 5.75 while retaining a Hold rating, reported. The two revisions show how valuation is being recalibrated around execution rather than product novelty.

Quarterly revenue beats estimates

RxSight generated USD 33.74 million in Q2 2026 revenue, exceeding the USD 32.55 million consensus estimate by USD 1.19 million, or 3.7 percent, according to MarketBeat. Adjusted loss was USD 0.29 per share against an expected USD 0.33 loss.

The sequential comparison was better: revenue rose from USD 30.893 million in Q1 2026 to USD 33.741 million in Q2 2026, an increase of 9.2 percent. However, the company still reported a consolidated net loss of USD 12.097 million in Q2 2026, keeping profitability central to the investment case.

Execution remains the key test

At the Wells Fargo Healthcare Conference on September 9, 2026, management presented a turnaround plan centered on renewed Light Adjustable Lens growth, while coverage of the event highlighted flat to declining commercial performance and withdrawn 2026 guidance, according to Quartr. That makes utilization and sales execution more important than the quarterly revenue beat alone.

Stock trades near yearly low

RxSight stock was valued at USD 4.85 on Nasdaq after hours on September 23, 2026, with a market capitalization of USD 200,773,554. Its 52-week range was USD 4.48 to USD 13.22, placing the quote USD 8.37 below the yearly high and USD 0.37 above the low.